Skip to main content
Erschienen in: Hepatology International 4/2013

01.10.2013 | Original Article

Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance

verfasst von: Dong Hyun Sinn, Jieun Yi, Moon Seok Choi, Dongil Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo

Erschienen in: Hepatology International | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Initial presentation of hepatocellular carcinoma (HCC) at an advanced stage in patients under a regular surveillance program is a devastating problem.

Aims

We assessed the prevalence and factors associated with this surveillance failure.

Methods

A total of 304 HCC patients who received regular surveillance were retrospectively reviewed. Surveillance failure was defined when the tumor was diagnosed at beyond the Milan criteria.

Results

Surveillance failure rate was 5.9 %. Macronodular cirrhosis (MC), ultrasonography-only surveillance (US-S) and infiltrative tumor type were independent factors associated with surveillance failure. The surveillance failure rate was higher in patients with MC (10.3 vs. 3.2 %, p = 0.022), US-S (14.6 vs. 4.3 %, p = 0.013) and when the tumor was infiltrative type (57.1 vs. 2.1 %, p < 0.001). Based on the two baseline factors (MC and US-S), the surveillance failure rates were 35.7, 6.8, 5.9 and 2.6 % for MC(+)/US-S(+), MC(+)/US-S(−), MC(−)/US-S(+) and MC(−)/US-S(−), respectively (p < 0.001).

Conclusion

The HCC surveillance failure was not rare in clinical practice. These data suggest that special attention for surveillance failure might be needed for patients with MC who receive US-S.
Literatur
1.
Zurück zum Zitat Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108–S112PubMedCrossRef Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108–S112PubMedCrossRef
2.
Zurück zum Zitat Park NH, Song IH, Chung YH. Molecular pathogenesis of hepatitis-B-virus-associated hepatocellular carcinoma. Gut Liver 2007;1:101–117PubMedCrossRef Park NH, Song IH, Chung YH. Molecular pathogenesis of hepatitis-B-virus-associated hepatocellular carcinoma. Gut Liver 2007;1:101–117PubMedCrossRef
3.
Zurück zum Zitat Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022PubMedCrossRef Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022PubMedCrossRef
4.
Zurück zum Zitat Lee HC. Noninvasive diagnostic criteria for hepatocellular carcinoma. Clin Mol Hepatol 2012;18:174–177PubMedCrossRef Lee HC. Noninvasive diagnostic criteria for hepatocellular carcinoma. Clin Mol Hepatol 2012;18:174–177PubMedCrossRef
5.
Zurück zum Zitat Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–474PubMedCrossRef Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–474PubMedCrossRef
6.
Zurück zum Zitat Suh DJ, Jeong SH. Current status of hepatitis C virus infection in Korea. Intervirology 2006;49:70–75PubMedCrossRef Suh DJ, Jeong SH. Current status of hepatitis C virus infection in Korea. Intervirology 2006;49:70–75PubMedCrossRef
7.
Zurück zum Zitat Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004;10:88–98PubMed Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004;10:88–98PubMed
8.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699PubMedCrossRef Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699PubMedCrossRef
9.
Zurück zum Zitat Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases. Radiology 2003;227:89–94PubMedCrossRef Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases. Radiology 2003;227:89–94PubMedCrossRef
10.
Zurück zum Zitat Wang JH, Changchien CS, Hung CH, Eng HL, Tung WC, Kee KM, et al. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol 2009;44:439–446PubMedCrossRef Wang JH, Changchien CS, Hung CH, Eng HL, Tung WC, Kee KM, et al. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol 2009;44:439–446PubMedCrossRef
11.
Zurück zum Zitat Seror O, N’Kontchou G, Haddar D, Dordea M, Ajavon Y, Ganne N, et al. Large infiltrative hepatocellular carcinomas: treatment with percutaneous intraarterial ethanol injection alone or in combination with conventional percutaneous ethanol injection. Radiology 2005;234:299–309PubMedCrossRef Seror O, N’Kontchou G, Haddar D, Dordea M, Ajavon Y, Ganne N, et al. Large infiltrative hepatocellular carcinomas: treatment with percutaneous intraarterial ethanol injection alone or in combination with conventional percutaneous ethanol injection. Radiology 2005;234:299–309PubMedCrossRef
12.
Zurück zum Zitat Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9:161–167PubMedCrossRef Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9:161–167PubMedCrossRef
13.
Zurück zum Zitat Myung SJ, Yoon JH, Kim KM, Gwak GY, Kim YJ, Yu JW, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006;53:266–270PubMed Myung SJ, Yoon JH, Kim KM, Gwak GY, Kim YJ, Yu JW, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006;53:266–270PubMed
14.
Zurück zum Zitat Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987–1997PubMedCrossRef Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987–1997PubMedCrossRef
15.
Zurück zum Zitat Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251–259PubMedCrossRef Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251–259PubMedCrossRef
16.
Zurück zum Zitat Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977–985PubMedCrossRef Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977–985PubMedCrossRef
17.
Zurück zum Zitat Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnù L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734–744PubMedCrossRef Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnù L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734–744PubMedCrossRef
18.
Zurück zum Zitat Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003;102:78–82PubMedCrossRef Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003;102:78–82PubMedCrossRef
19.
Zurück zum Zitat Kim do Y, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology 2011;81(Suppl 1):56–60PubMedCrossRef Kim do Y, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology 2011;81(Suppl 1):56–60PubMedCrossRef
20.
Zurück zum Zitat Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol 2010;23:276–283PubMedCrossRef Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol 2010;23:276–283PubMedCrossRef
21.
Zurück zum Zitat Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109–162CrossRef Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109–162CrossRef
Metadaten
Titel
Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance
verfasst von
Dong Hyun Sinn
Jieun Yi
Moon Seok Choi
Dongil Choi
Geum-Youn Gwak
Yong-Han Paik
Joon Hyeok Lee
Kwang Cheol Koh
Seung Woon Paik
Byung Chul Yoo
Publikationsdatum
01.10.2013
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 4/2013
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-013-9462-z

Weitere Artikel der Ausgabe 4/2013

Hepatology International 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.